Chronic Myeloproliferative Disorders Completed Phase 1 Trials for Fenretinide (DB05076)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00104923Fenretinide in Treating Patients With Refractory or Relapsed Hematologic CancerTreatment